The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Innovative approaches in the formulation of biologics will be shared in this session. Topics covered will include exploring the strategies in the development of formulations to support co-formulation of drug products and different routes of administration. The use of nanoparticles in the development and delivery of mRNA therapeutics as well as the use of application of novel freezing and drying technique will be explored. The session will also include an interactive panel discussion following the presentations.
The morning session will focus on comparability for novel protein-based modalities. The afternoon session will focus on comparability for mRNA vaccines and microbiome products…
With the endorsement from ICH Management Committee in 2018 to introduce a new quality guideline for Analytical Development (ICH Q14) and a complementary revision of ICH Q2(R1) for Validation of Analytical Procedures, product owners will gain further guidance on enhanced approaches to analytical met…
In-depth analytical characterization of biological drugs and vaccines is important to aid in their development, and innovation in analytical technologies is crucial for the advancement of complex modalities…
Laura Sepp-Lorenzino, Ph.D. joined Intellia Therapeutics in 2019 as Chief Scientific Officer and is responsible for Research and Early Development. Intellia is harnessing CRISPR-based technologies to revolutionize the future of medicine…